Indonesia looking for its own COVID-19 immunization in the midst of stress over access Kumar Jeetendra | July 2, 2020 Indonesia has been operating to produce its COVID-19 vaccine following year, thanks to growing anxiety that developing nations could have trouble getting access to a future jab, the head of Indonesia’s national COVID-19 research staff said Thursday. “The production capability and ability of biotech businesses in the world is, we understand, limited, and global supply …
New mass spectrometry-based test recognizes coronavirus in wash arrangements of patients Kumar Jeetendra | July 16, 2020 Pharmacists in Martin Luther University Halle-Wittenberg (MLU) have succeeded in detecting small amounts of coronavirus SARS-CoV-2 utilizing mass spectrometry. Because of their own investigation , they used naturopathic remedies of COVID-19 patients. The publication method might supplement conventional tests. It’s undergoing developments and could be available as standard diagnostic tool for COVID-19 in the future. …
Test mRNA-based COVID-19 immunization evokes defensive safe reactions in animals Kumar Jeetendra | July 25, 2020 Two injections of this vaccine were enough to induce robust immunity, completely preventing SARS-CoV-2 infection in mice. MRNA-based vaccines are all attractive options for protecting against SARS-CoV-2 because they may be quickly designed and manufactured at a huge scale within weeks. Moreover, preclinical studies have shown that mRNA-based vaccines cause potent and broadly protective immune …
Waterloo Technology profiles Compounds in blood of COVID-19 Sufferers Kumar Jeetendra | July 29, 2020 A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses such as cancer and COVID-19, is expanding operations with the support of a 5-million USD investment. Bin Ma, a University of Waterloo computer engineering professor who co-founded Rapid Novor at 2015, says that the company’s technologies is the most …
Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups Kumar Jeetendra | August 1, 2020 HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated …
FDA authorizes initial two COVID-19 serology tests Kumar Jeetendra | August 2, 2020 Today, the U.S. Food and Drug Administration approved the initial two COVID-19 serology tests which show an estimated amount of antibodies within somebody’s blood. Both tests from Siemens, the ADVIA Centaur COV2G and Attelica COV2G are what are known as”semi-quantitative” evaluations, meaning that they don’t show an exact measurement, but estimate the number of a …
Quicker Test for Covid-19 Antibodies Kumar Jeetendra | August 5, 2020 A team of Swiss-German researchers has developed a method of testing for neutralizing antibodies against SARS-CoV-2 that creates a result in half the time of traditional tests. A conventional neutralization test to determine immunity to SARS-CoV-2 usually takes two to three days and has to be carried out with infectious coronaviruses in a lab resorting …
CARE consortium dispatches to quicken drug discovery and improvement for COVID-19 Kumar Jeetendra | August 19, 2020 Using a grant approximately $77.7 million, CARE is funded by cash donations by the European Union (EU) and money and in-kind contributions from Australian European Federation of Pharmaceutical Industries and Associations (EFPIA) businesses and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, …
Russia finishes early preliminaries of second potential COVID-19 immunization: Report Kumar Jeetendra | September 8, 2020 Siberia’s Vector virology institute on September 8 finished early-stage human trials, called Phase II, of a second possible Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying. Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August after finishing early-stage human trials. “Today… …
CRISPR-based framework smothers qualities identified with AAV antibody production Kumar Jeetendra | September 9, 2020 Gene therapy generally is based on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In the event of CRISPR-based gene therapies, molecular scissors can then snip out a faulty gene, add in a missing arrangement or enact a temporary change in its expression, but the body’s immune response to AAV can …
ICMR gives positive nod for HiMedia-Syngene COVID-19 antibody test kit, ELISafe19™ Kumar Jeetendra | September 10, 2020 The Indian Bioscience leader, Himedia Laboratories, an expert in media developer, manufacturer and diagnostics, has manufactured an IgG based ELISA test kit, ELISafe19™ for COVID-19 in collaboration with Syngene International, an integrated research and development services company. The antibody test kit has a sensitivity of 100% and specificity of 99% and has now been approved by …
China favors first nasal spray COVID-19 antibody for preliminaries Kumar Jeetendra | September 10, 2020 China has approved for trials its initial nasal spray vaccine to combat the novel coronavirus that has claimed over 904,000 lives and infected more than 27 million people globally, official media here reported on September 10. China’s only nasal spray vaccine against the coronavirus is anticipated to start phase I clinical trials in November, and …
